A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas Amgen

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas Amgen

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ganitumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GAMMA
  • Sponsors Amgen
  • Most Recent Events

    • 08 Aug 2012 Status changed from recruiting to discontinued.
    • 14 Jun 2012 Additional trial location (Bulgaria) added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Interim tolerability analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top